MIMIC

Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management

Retrieved on: 
목요일, 5월 9, 2024
Flagship Pioneering, Machine learning, Partnership, Research, Flagship, Obesity, Disease, Therapy, Novo Nordisk, Panasonic Executive Partner, Molecular mimicry, Biology, Drug development, MIMIC

CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.

Key Points: 
  • The collaboration is signed under the broader strategic partnership between Novo Nordisk and Flagship Pioneering to develop a portfolio of novel treatment approaches for cardiometabolic and rare diseases.
  • Metaphore will work jointly with Pioneering Medicines and Novo Nordisk to advance the programs through foundational activities and preclinical development, after which point Novo Nordisk could advance the programs into clinical studies.
  • Metaphore is the third Flagship-founded company to advance research programs under the strategic partnership between Novo Nordisk and Flagship Pioneering following programs with Omega Therapeutics and Cellarity which were announced earlier this year.
  • Novo Nordisk will also reimburse R&D costs and participate in a future financing round for Metaphore.

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

Retrieved on: 
화요일, 5월 16, 2023
Acker, Biological engineering, University, Ragon Institute, Microbiology, Therapy, Doctor of Philosophy, Genomics, Business operations, Boston Children's Hospital, MIMIC, Core, Metabolism, MBA, MIT, Associate, Harvard Medical School, Committee, University of Colorado Boulder, Flagship Pioneering, Patient, Nature, Machine learning, University of Colorado Boulder Computer Science Department, Drug discovery, Hospital, Autoimmunity, Pharmaceutical industry, Management, Metaphor, Flagship

CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.

Key Points: 
  • With $50 million in committed capital from Flagship, Metaphore has built a first-in-class bioplatform during the past two years
    CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.
  • said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of Metaphore.
  • We believe this approach has the potential to unlock breakthroughs that outperform today's drugs and reach patients with few or no therapeutic options."
  • Metaphore's leadership team includes Amanda Kay, Ph.D., Flagship Pioneering Operating Partner and President of Metaphore, former CBO Deep Genomics, and COO Pfizer Inflammation & Immunology; Chaz Hinzman, Ph.D., Flagship Pioneering Associate and Head of Business Operations for Metaphore; and Marcin Paduch, Ph.D., Head of Platform at Metaphore.